Theoretical Basis, State and Challenges of Living Cell-based Drug Delivery Systems

Overview

Journal Theranostics

Date 2024 Sep 13

PMID 39267776

Authors

Wei Liu

Guowang Cheng

Hao Cui

Zhen Tian

Bowen Li

Yanhua Han

Jia-Xin Wu

Jie Sun

Yuyue Zhao

Tongkai Chen

Guangtao Yu

Affiliations

Soon will be listed here.

Abstract

The therapeutic efficacy of drugs is determined, to a certain extent, by the efficiency of drug delivery. The low efficiency of drug delivery systems (DDSs) is frequently associated with serious toxic side effects and can even prove fatal in certain cases. With the rapid development of technology, drug delivery has evolved from using traditional frameworks to using nano DDSs (NDDSs), endogenous biomaterials DDSs (EBDDSs), and living cell DDSs (LCDDSs). LCDDSs are receiving widespread attention from researchers at present owing to the unique advantages of living cells in targeted drug delivery, including their excellent biocompatibility properties, low immunogenicity, unique biological properties and functions, and role in the treatment of diseases. However, the theoretical basis and techniques involved in the application of LCDDSs have not been extensively summarized to date. Therefore, this review comprehensively summarizes the properties and applications of living cells, elaborates the various drug loading approaches and controlled drug release, and discusses the results of clinical trials. The review also discusses the current shortcomings and prospects for the future development of LCDDSs, which will serve as highly valuable insights for the development and clinical transformation of LCDDSs in the future.

References

Li S, Li L, Lin X, Chen C, Luo C, Huang Y . Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis. ACS Nano. 2021; 16(1):50-67. DOI: 10.1021/acsnano.1c06022. View

Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L . Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022; 14(656):eabn1128. DOI: 10.1126/scitranslmed.abn1128. View

Morgenroth A, Baazaoui F, Hosseinnejad A, Schafer L, Vogg A, Singh S . Neural Stem Cells as Carriers of Nucleoside-Conjugated Nanogels: A New Approach toward Cell-Mediated Delivery. ACS Appl Mater Interfaces. 2023; 15(18):21792-21803. PMC: 10176478. DOI: 10.1021/acsami.2c23283. View

Hogrebe N, Maxwell K, Augsornworawat P, Millman J . Generation of insulin-producing pancreatic β cells from multiple human stem cell lines. Nat Protoc. 2021; 16(9):4109-4143. PMC: 8529911. DOI: 10.1038/s41596-021-00560-y. View

Charlesworth C, Hsu I, Wilkinson A, Nakauchi H . Immunological barriers to haematopoietic stem cell gene therapy. Nat Rev Immunol. 2022; 22(12):719-733. PMC: 8929255. DOI: 10.1038/s41577-022-00698-0. View

Yao Q, Yang G, Wang H, Liu J, Zheng J, Lv B . Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment. Drug Deliv. 2021; 28(1):1455-1465. PMC: 8274500. DOI: 10.1080/10717544.2021.1949075. View

Dundas C, DeMonte D, Park S . Streptavidin-biotin technology: improvements and innovations in chemical and biological applications. Appl Microbiol Biotechnol. 2013; 97(21):9343-53. DOI: 10.1007/s00253-013-5232-z. View

Christ B, Bruckner S, Winkler S . The Therapeutic Promise of Mesenchymal Stem Cells for Liver Restoration. Trends Mol Med. 2015; 21(11):673-686. DOI: 10.1016/j.molmed.2015.09.004. View

Xu X, Kwong C, Li J, Wei J, Wang R . "Zombie" Macrophages for Targeted Drug Delivery to Treat Acute Pneumonia. ACS Appl Mater Interfaces. 2023; 15(24):29012-29022. DOI: 10.1021/acsami.3c06025. View

10.

Zhao Z, Yang Y, Sheng T, Bao Y, Yu R, Yu X . Platelet-Drug Conjugates Engineered via One-step Fusion Approach for Metastatic and Postoperative Cancer Treatment. Angew Chem Int Ed Engl. 2024; 63(37):e202403541. DOI: 10.1002/anie.202403541. View

11.

Wang Z, Pan J, Yuan R, Chen M, Guo X, Zhou S . Shell-Sheddable Polymeric Micelles Alleviate Oxidative Stress and Inflammation for Enhanced Ischemic Stroke Therapy. Nano Lett. 2023; 23(14):6544-6552. DOI: 10.1021/acs.nanolett.3c01567. View

12.

Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R . Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy. Adv Sci (Weinh). 2021; 9(5):e2103444. PMC: 8844476. DOI: 10.1002/advs.202103444. View

13.

Cai D, Gao W, Li Z, Zhang Y, Xiao L, Xiao Y . Current Development of Nano-Drug Delivery to Target Macrophages. Biomedicines. 2022; 10(5). PMC: 9139084. DOI: 10.3390/biomedicines10051203. View

14.

Ortiz-Otero N, Marshall J, Lash B, King M . Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells. Nanoscale Adv. 2022; 2(9):3942-3953. PMC: 9419179. DOI: 10.1039/d0na00271b. View

15.

Cao Z, Li D, Zhao L, Liu M, Ma P, Luo Y . Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery. Nat Commun. 2022; 13(1):2038. PMC: 9018704. DOI: 10.1038/s41467-022-29693-8. View

16.

Liu Y, Yu Y, Wang M, Zhang C, Li C . Recent progress in therapeutic strategies and biomimetic nanomedicines based on neutrophils for inflammation treatment. Nanomedicine (Lond). 2023; 18(5):485-500. DOI: 10.2217/nnm-2022-0211. View

17.

Xiao Q, Zoulikha M, Qiu M, Teng C, Lin C, Li X . The effects of protein corona on in vivo fate of nanocarriers. Adv Drug Deliv Rev. 2022; 186:114356. DOI: 10.1016/j.addr.2022.114356. View

18.

Lou S, Duan Y, Nie H, Cui X, Du J, Yao Y . Mesenchymal stem cells: Biological characteristics and application in disease therapy. Biochimie. 2021; 185:9-21. DOI: 10.1016/j.biochi.2021.03.003. View

19.

Duckert B, Vinkx S, Braeken D, Fauvart M . Single-cell transfection technologies for cell therapies and gene editing. J Control Release. 2020; 330:963-975. DOI: 10.1016/j.jconrel.2020.10.068. View

20.

Shao J, Feng L, Zhao Q, Chen C, Li J, Ma Q . Erythrocyte-mimicking subcutaneous platform with a laser-controlled treatment against diabetes. J Control Release. 2021; 341:261-271. DOI: 10.1016/j.jconrel.2021.11.021. View